The biopharmaceutical CDMO industry has recently experienced increasing levels of consolidation. Meanwhile, investment in innovative technology platforms and services is rapidly growing in support of the rich pipeline of breakthrough biologics. These transformations in the CDMO industry present exciting growth opportunities as well as challenges for CDMOs making capability and capacity investment decisions. BioPharm International recently spoke with Konstantin Matentzoglu, CEO of Celonic AG, about promising opportunities and trends shaping the CDMO landscape, as well as the value of a manufacturing partner rejuvenating its biologics services portfolio, forging strategic alliances, and driving global commercial expansion models.